Chalcones Display Anti-NLRP3 Inflammasome Activity in Macrophages through Inhibition of Both Priming and Activation Steps-Structure-Activity-Relationship and Mechanism Studies.
Adenosine Triphosphate
/ pharmacology
Caspase 1
/ metabolism
Cell Line
Chalcones
/ pharmacology
Dimerization
Humans
Inflammasomes
/ drug effects
Interleukin-1beta
/ metabolism
Lipopolysaccharides
/ pharmacology
Macrophages
/ cytology
NF-KappaB Inhibitor alpha
/ metabolism
NF-kappa B
/ metabolism
NLR Family, Pyrin Domain-Containing 3 Protein
/ metabolism
Phosphorylation
/ drug effects
Pyroptosis
/ drug effects
Structure-Activity Relationship
ATP
K+ efflux
NF-ĸB
NLRP3 inflammasome
chalcone
structure-activity relationship
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
16 Dec 2020
16 Dec 2020
Historique:
received:
06
10
2020
revised:
11
12
2020
accepted:
13
12
2020
entrez:
19
12
2020
pubmed:
20
12
2020
medline:
3
9
2021
Statut:
epublish
Résumé
Chalcones are responsible for biological activity throughout fruits, vegetables, and medicinal plants in preventing and treating a variety of inflammation-related diseases. However, their structure-activity relationship (SAR) in inhibiting inflammasome activation has not been explored. We synthesized numerous chalcones and determined their SAR on lipopolysaccharide (LPS)-primed ATP-induced NLRP3 inflammasome activation. 11Cha1 displayed good inhibitory activity on release reaction of caspase-1, IL-1β, and IL-18. It significantly inhibited LPS-induced phosphorylation and proteolytic degradation of IĸB-α and nuclear translocation of NF-ĸB, but had little effect on mitogen-activated protein kinases (MAPKs) activities. Furthermore, 11Cha1 blocked LPS-induced up-regulation of NLRP3, pro-caspase-1, ASC, IL-18, and IL-1β, indicating the suppression on priming step of inflammasome activation. ASC dimerization and oligomerization are considered to be direct evidence for inflammasome activation. 11Cha1 profoundly inhibited ATP-induced formation of ASC dimers, trimers, and oligomers, and the assembly of ASC, pro-caspase-1, and NLRP3 in inflammasome formation. Decrease of intracellular K
Identifiants
pubmed: 33339319
pii: molecules25245960
doi: 10.3390/molecules25245960
pmc: PMC7767297
pii:
doi:
Substances chimiques
Chalcones
0
Inflammasomes
0
Interleukin-1beta
0
Lipopolysaccharides
0
NF-kappa B
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
NF-KappaB Inhibitor alpha
139874-52-5
Adenosine Triphosphate
8L70Q75FXE
Caspase 1
EC 3.4.22.36
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 107-2320-B-002-018-MY3 and MOST 106-2320-B-002 -005 -MY3
Références
Front Pharmacol. 2018 Oct 02;9:1123
pubmed: 30333752
Cell Death Dis. 2019 Feb 12;10(2):128
pubmed: 30755589
J Immunol. 2009 Jul 15;183(2):792-6
pubmed: 19542372
Immunity. 2013 Jun 27;38(6):1142-53
pubmed: 23809161
J Immunol. 2014 Apr 15;192(8):3881-8
pubmed: 24623131
J Leukoc Biol. 2014 Dec;96(6):1087-100
pubmed: 25210146
Molecules. 2020 Feb 28;25(5):
pubmed: 32121151
Adv Exp Med Biol. 2019;1172:143-155
pubmed: 31628655
J Immunol. 2009 Jul 15;183(2):787-91
pubmed: 19570822
Food Funct. 2019 Jan 22;10(1):422-431
pubmed: 30604787
Front Immunol. 2019 Feb 28;10:276
pubmed: 30873162
Int J Mol Sci. 2019 Jan 14;20(2):
pubmed: 30646518
Blood. 2010 Jul 1;115(26):5398-400
pubmed: 20407038
Cell Death Dis. 2019 Apr 5;10(4):313
pubmed: 30952839
Trends Mol Med. 2007 Nov;13(11):460-9
pubmed: 18029230
Front Pharmacol. 2019 May 28;10:573
pubmed: 31191313
Int J Mol Sci. 2019 Jun 13;20(12):
pubmed: 31200447
Int J Mol Sci. 2019 Dec 10;20(24):
pubmed: 31835548
Immunity. 2016 Oct 18;45(4):761-773
pubmed: 27692612
Int Immunopharmacol. 2020 Jul;84:106498
pubmed: 32304996
Alcohol Clin Exp Res. 2019 Aug;43(8):1662-1671
pubmed: 31162673
Antioxid Redox Signal. 2015 May 1;22(13):1111-29
pubmed: 25330206
J Exp Med. 2018 May 7;215(5):1315-1325
pubmed: 29549113
Trends Immunol. 2019 Nov;40(11):1035-1052
pubmed: 31662274
Front Immunol. 2018 Oct 08;9:2305
pubmed: 30349539
Curr Pharm Des. 2018;24(14):1449-1484
pubmed: 29589535
Trends Biochem Sci. 2016 Dec;41(12):1012-1021
pubmed: 27669650
Front Oncol. 2019 Nov 12;9:1220
pubmed: 31781509
Br J Dermatol. 2014 Apr;170(4):816-23
pubmed: 24734946
Bioorg Chem. 2020 May;98:103748
pubmed: 32179281
Mol Neurobiol. 2018 Feb;55(2):1082-1096
pubmed: 28092085
Exp Neurobiol. 2014 Jun;23(2):163-8
pubmed: 24963281
Front Pharmacol. 2020 Apr 22;11:483
pubmed: 32390839
J Immunol. 2011 Jul 15;187(2):613-7
pubmed: 21677136
Med Chem Res. 2015 Apr;24(4):1672-1680
pubmed: 25866456
Annu Rev Immunol. 2011;29:707-35
pubmed: 21219188
Cardiovasc Res. 2010 May 1;86(2):211-8
pubmed: 20202975
Science. 2010 Jan 15;327(5963):296-300
pubmed: 20075245
J Nutr Sci. 2016 Dec 29;5:e47
pubmed: 28620474
Phytother Res. 2018 Dec;32(12):2551-2559
pubmed: 30281174
Front Pharmacol. 2020 Jan 31;10:1626
pubmed: 32082152
Mol Cell. 2017 Oct 5;68(1):185-197.e6
pubmed: 28943315
Int J Mol Sci. 2019 Jul 06;20(13):
pubmed: 31284572
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Nature. 2016 Feb 18;530(7590):354-7
pubmed: 26814970